Prospective Collaborative Study for pulse dexamethasone and lenalidomide in Relapsed / Refractory Langerhans cell histiocytosis (LENDEXLCH study)

RAMYA UPPULURI0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年10月17日

试验速览

暂无简介。

•1.Patients from 1 year of age to 18 years of age with biopsy proven LCH
•2.Relapsed or refractory disease after having received 6 to 12 weeks of induction chemotherapy with Vinblastine plus prednisolone as per LCH II or III protocol
•3.Relapsed or refractory disease after receiving salvage chemotherapy with cladribine +/- cytarabine can also be included
•4.Patients with low-risk disease at the time of relapse may be offered LenDex upfront
•5.Patients with high-risk disease at the time of relapse may be offered LenDex upfront or after salvage treatment, based on the discretion of the treating physician

•1.Pregnancy or lactation
•2.Patients with renal impairment defined as a serum creatinine > 1
•3.Patients with liver impairment (excluding those due to disease) defined as SGPT and/or PT more than 5 times the upper limit of normal
•4.Patients with pre-existing peripheral neuropathy

发起方

RAMYA UPPULURI